News in genomics

Things are as usual moving at ludicrous speed in the world of genomics, but sadly I only have time to post a few pointers to some of the most striking developments.

IBM is moving into the third-generation sequencing arena. The company is developing a new sequencing technology based on tiny nanopores - a field already being explored by the understated British nobility of sequencing, Oxford Nanopore. This is all over the news, but Dan Vorhaus has an introduction and is promising to follow up on further developments. You can also watch a pretty but largely content-free animation of the process.
Speaking of Dan Vorhaus: the superb blog Genomics Law Report has just launched a new series, What ELSI is New, consisting of brief guest posts from a diverse range of authors on emerging ethical, legal and social issues in genomics. Already there have been two instalments posted, one from Hank Greely and another from Misha Angrist - both well worth a read. I have also committed to writing my own contribution (it's on its way, Dan!).
Finally, a new program at Beth Israel Deaconess Medical Center will push medical students trainee pathologists towards a better understanding of new genetic tests:

Doctors in their second and final years of pathology residency training will take the class - attending lectures and researching the science behind the tests. If they choose, they can look at their own test results, submitting a sample to the genetic testing company Navigenics.

Given that 23andMe now dominates the genome scan market (meaning it will be the company most prospective patients will be using), and that the company plans to offer discounted tests to doctors, Navigenics seems like a strange choice.
Categories

More like this

This piece in Newsweek is a neat summary of the rise and fall of Icelandic genomics giant deCODE Genetics. Regular readers of Genetic Future will be aware that the company has been steadily bleeding capital ever since its launch over a decade ago, and recently declared formal bankruptcy. Since then…
IBM's announcement that it will be entering the DNA sequencing technology race (which I mentioned briefly earlier today) has created a tremendous amount of mainstream media interest. That's understandable given IBM's size and history of innovation, but how likely are they to represent serious…
Added in edit: for superb analysis of the announcement from multiple angles, you should also check out Dan Vorhaus' three incisive articles on Genomics Law Report. Personal genomics company 23andMe announced yesterday on its blog (and in an email to customers) of impending changes to its product…
(Cross-posted to Genomes Unzipped.) Today's US Congress Committee on Energy and Commerce hearing into the direct-to-consumer genetic testing industry was a vicious affair. Representatives from testing companies 23andMe, Navigenics and Pathway faced a barrage of questions about the accuracy and…

Just a point of clarification re: the program at Beth Israel Deaconess...its focus is on residents in the pathology program (i.e., post-M.D.) rather than on medical students. Should be interesting to see how it goes!